AMARIN APPOINTS DECLAN DOOGAN TO NEW POSITION OF
PRESIDENT-RESEARCH AND DEVELOPMENT
Former Pfizer Head-Global Research & Development Brings Wealth of
Knowledge and Industry Experience
LONDON, United Kingdom, April 10, 2007, Amarin Corporation plc (NASDAQ: AMRN) (“Amarin” or
"Company") today announced the appointment of Declan Doogan, M.D. to the newly-created position of
President, Research & Development.
Most recently, Dr. Doogan was Senior Vice President and Head of Worldwide Development at Pfizer Global
Research & Development. In recent years, he held a number of senior positions in Pfizer in the US and the
UK. Dr. Doogan joined Pfizer in 1982, where he led the Zoloft clinical development program. He held positions
in the UK and in Japan, where he was initially Medical Director and later head of the company’s development
organization. Dr. Doogan holds a Visiting Professorship of Drug Development Science with Kitasato University in
Japan. In addition, Dr. Doogan holds a number of non-executive directorships in the US and the UK.
Dr. Doogan received his medical degree from Glasgow University in 1975. He is a Fellow of the Royal College
of Physicians of Glasgow and the Faculty of Pharmaceutical Medicine in the UK.
Mr. Rick Stewart, Amarin’s Chief Executive Officer, commented,
“We are delighted that Declan is joining the Amarin team. His experience will be invaluable in the effective
management and integration of our research, development, clinical and medical affairs activities. Declan brings to
Amarin both a clear understanding of what it takes to bring products through to market and a strategic
understanding of how to manage a drug development portfolio. We are confident he will provide strong
leadership, and will successfully manage and advance our pipeline in central nervous system (CNS) disorders.”
Dr. Doogan commented on his appointment,
“Now is a particularly exciting time in the CNS field, so I am deli